Caas Capital Management LP Rallybio Corp Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$4.31 - $8.89 $572,617 - $1.18 Million
-132,858 Reduced 80.85%
31,470 $178,000
Q1 2023

May 15, 2023
SELL
$4.37 - $8.75 $425,721 - $852,416
-97,419 Reduced 37.22%
164,328 $938,000
Q4 2022

Feb 14, 2023
BUY
$4.67 - $14.86 $1.22 Million - $3.89 Million
261,747 New
261,747 $1.72 Million
Q4 2021

Feb 14, 2022
SELL
$9.3 - $19.91 $93,000 - $199,100
-10,000 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$10.83 - $23.4 $108,300 - $234,000
10,000 New
10,000 $176,000

Others Institutions Holding RLYB

# of Institutions
52
Shares Held
31.9M
Call Options Held
0
Put Options Held
0
View Full List

About Rallybio Corp

RLYB Quotes by TradingView
  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $31.8M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email